ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Stemness Analysis Uncovers That The Peroxisome Proliferator-Activated Receptor Signaling Pathway Can Mediate Fatty Acid Homeostasis In Sorafenib-Resistant Hepatocellular Carcinoma Cells

Feng, Tingze; Wu, Tianzhi; Zhang, Yanxia; Zhou, Lang; Liu, Shanshan; Li, Lin; Li, Ming; Hu, Erqiang; Wang, Qianwen; Fu, Xiaocong; Zhan, Li; Xie, Zijing; Xie, Wenqin; Huang, Xianying*; Shang, Xuan*; Yu, Guangchuang*南方医科大学
Frontiers in Oncology2022-7-22DOI: 10.3389/fonc.2022.912694
7被引4阅读
引用收藏
分享

摘要

Hepatocellular carcinoma (HCC) stem cells are regarded as an important part of individualized HCC treatment and sorafenib resistance. However, there is lacking systematic assessment of stem-like indices and associations with a response of sorafenib in HCC. Our study thus aimed to evaluate the status of tumor dedifferentiation for HCC and further identify the regulatory mechanisms under the condition of resistance to sorafenib. Datasets of HCC, including messenger RNAs (mRNAs) expression, somatic mutation, and clinical information were collected. The mRNA expression-based stemness index (mRNAsi), which can represent degrees of dedifferentiation of HCC samples, was calculated to predict drug response of sorafenib therapy and prognosis. Next, unsupervised cluster analysis was conducted to distinguish mRNAsi-based subgroups, and gene/geneset functional enrichment analysis was employed to identify key sorafenib resistance-related pathways. In addition, we analyzed and confirmed the regulation of key genes discovered in this study by combining other omics data. Finally, Luciferase reporter assays were performed to validate their regulation. Our study demonstrated that the stemness index obtained from transcriptomic is a promising biomarker to predict the response of sorafenib therapy and the prognosis in HCC. We revealed the peroxisome proliferator-activated receptor signaling pathway (the PPAR signaling pathway), related to fatty acid biosynthesis, that was a potential sorafenib resistance pathway that had not been reported before. By analyzing the core regulatory genes of the PPAR signaling pathway, we identified four candidate target genes, retinoid X receptor beta (RXRB), nuclear receptor subfamily 1 group H member 3 (NR1H3), cytochrome P450 family 8 subfamily B member 1 (CYP8B1) and stearoyl-CoA desaturase (SCD), as a signature to distinguish the response of sorafenib. We proposed and validated that the RXRB and NR1H3 could directly regulate NR1H3 and SCD, respectively. Our results suggest that the combined use of SCD inhibitors and sorafenib may be a promising therapeutic approach.

学科与关键词

关键词
hepatocellular carcinomasorafenib resistancePPAR signaling pathwaystemness indexprognosis
相关
加载中…
  • Implications of Stemness Features in 1059 Hepatocellular Carcinoma Patients from Five Cohorts: Prognosis, Treatment Response, and Identification of Potential Compounds
    Mai, Haoming; Xie, Haisheng; Luo, Mengqi; Hou, Jia; Chen, Jiaxuan; Hou, Jinlin*; Jiang, De-ke*Cancers, 2022, 14(3): 563.被引 8
  • FXYD5 promotes sorafenib resistance through the Akt/mTOR signaling pathway in hepatocellular carcinoma
    Tan, Xiang-Peng; Xiong, Ben-Han; Zhang, Yuan-Xu; Wang, Shen-Li; Zuo, Qian*; Li, Jing*European Journal of Pharmacology, 2022, 931: 175186.被引 5
  • Ahypoxia-related signature enhances the prediction of the prognosis in hepatocellular carcinoma patients and correlates with sorafenib treatment response
    Jiang, Hong-Ye; Ning, Gang; Wang, Yen-Sheng; Lv, Wei-Biao*American Journal of Translational Research, 2020, 12(12): 7762-7781.被引 14
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Oncology
发表日期
2022-07-22
卷期
第 12 卷
页码
912694
DOI
10.3389/fonc.2022.912694
期刊等级
3区
成果收录
SCIE

作者

  • F

    Feng, Tingze (第一作者)

    southern med univ

  • W

    Wu, Tianzhi

    southern med univ

查看全部 16 位作者收起作者
  • Z

    Zhang, Yanxia

    southern med univ

  • Z

    Zhou, Lang

    southern med univ

  • L

    Liu, Shanshan

    southern med univ

  • L

    Li, Lin

    southern med univ

  • L

    Li, Ming

    southern med univ

  • H

    Hu, Erqiang

    southern med univ

  • W

    Wang, Qianwen

    southern med univ

  • F

    Fu, Xiaocong

    southern med univ

  • Z

    Zhan, Li

    southern med univ

  • X

    Xie, Zijing

    southern med univ

  • X

    Xie, Wenqin

    southern med univ

  • H

    Huang, Xianying (通讯)

    southern med univ

  • S

    Shang, Xuan (通讯)

    southern med univ

  • Y

    Yu, Guangchuang (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417